NEW YORK — Quest Diagnostics said during its 2025 Investor Day meeting this week that it expects its Q1 2025 revenues to come in $25 million below previous expectations and its Q1 earnings per share to be $.10 below previous expectations due to a more severe than anticipated impact from weather during the quarter. It maintained its full-year 2025 guidance. In late January, the firm guided to 2025 revenues of between $10.70 billion and $10.85 billion. Adjusted EPS is expected to be between $9.55 and $9.80.
Revvity said this week that its Omics laboratory in Manchester, UK, will provide DNA sequencing services to help identify rare genetic conditions in newborns for Genomics England's Generation Study. The study involves the screening of up to 100,000 newborns for more than 200 rare genetic disorders, and the findings will be used to inform decisions on the use of whole-genome sequencing in newborn screening. Revvity announced in November that it would extract DNA from cord blood from samples collected from newborns for the study.
Life science firm Enzo Biochem this week reported that its fiscal second quarter revenues declined 14 percent to $7.3 million compared to the prior-year quarter due to the timing of a larger order and market slowdown in the US. The company reported a Q2 net loss of $1.5 million, or $.03 per share. Enzo ended the quarter with cash and cash equivalents of $40.3 million. The company said its plan to return to compliance with continued listing standards is currently under review by the New York Stock Exchange.
Indian precision oncology firm 4baseCare said this week that its genomics lab at Dubai Science Park has been accredited by the College of American Pathologists. The lab was established in partnership with United Arab Emirates-based next-generation sequencing provider Innovate Life Sciences. The two firms inked a deal last fall to offer 4baseCare’s genomic tests in Dubai.
Circular Genomics said this week that it is moving its corporate headquarters to Lilly Gateway Labs in San Diego, which is operated in partnership with Alexandria Real Estate Equities. Gateway Labs is an innovation hub that connects biotech companies to Eli Lilly's expertise. The company will use these resources to advance the development of diagnostic and prognostic blood tests for Alzheimer's disease based on the company's circular RNA (circRNA) biomarker technology. In September, Circular Genomics launched the early-access program for MindLight, its first circRNA biomarker-based blood test designed to predict the likelihood of whether a patient with major depressive disorder (MDD) will respond, or not, to selective serotonin reuptake inhibitor (SSRI) antidepressant treatment.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.